계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Cytheris
company
About
Cytheris is biopharmaceutical company focused on the R&D of therapies for immune modulation.
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $15M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 1999
- Operating Status
- Close
Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$45.70M
Cytheris has raised a total of
$45.70M
in funding over 2 rounds. Their latest funding was raised on
Jun 7, 2010 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 7, 2010 | Series D | $15M | 1 | — | — | Detail |
| Oct 25, 2006 | Series B | $30.70M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Cytheris is funded by 2 investors.
Bioam Gestion
and T2C2 Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Bioam Gestion
|
— | Series D |
T2C2 Capital
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
